Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/29/2005US20050215523 Administering nutritional or other product comprising gamma-cyclodextrin for for producing a blunted postprandial glycemic response
09/29/2005US20050215522 Blocks passage of the pathogen through lipid rafts in the membrane of a cell susceptible to the pathogen; especially for reducing the risk of infection with an enveloped immunodeficiency virus, T lymphotrophic virus or herpesvirus
09/29/2005US20050215521 Modafinil combination therapy for improving sleep quality
09/29/2005US20050215520 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
09/29/2005US20050215518 Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
09/29/2005US20050215517 Use of an anti-endotoxin drug in the prevention and treatment of disease
09/29/2005US20050215514 Topical applying 5-fluorouracil
09/29/2005US20050215513 Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound
09/29/2005US20050215502 Regulation of endogenous gene expression in cells using zinc finger proteins
09/29/2005US20050215500 aoaligonucleotides containing activated lymphocytes; antibody therapy; skin disorders; antiallergens
09/29/2005US20050215498 Method for the protection of endothelial and epithclial cells during chemotherapy
09/29/2005US20050215497 Treating prostate cancer by administering double stranded oligonucleotide having two complementary oligonucleotide sequences forming a hybrid; each sequence has at one 3' or 5' end 1-5 unpaired nucleotides forming single-strand ends extending beyond the hybrid
09/29/2005US20050215496 Preparation and diabetic use of Gibberellins
09/29/2005US20050215495 Macrolide antibiotics
09/29/2005US20050215494 Severe Acute Respiratory Syndrome (SARS); extracted and purified from the Chinese medicinal plant Scutellaria baicalensis Georgi
09/29/2005US20050215493 Calcium-containing tissue strengthening agents and use thereof
09/29/2005US20050215492 Ameliorant for chemical treament of cancer
09/29/2005US20050215490 Cultivating a Amycolatopsis orientalis strain under aerobic conditions, chemically modifying the product; antibiotics; anticarcinogenic agent, antiinflammatory agent
09/29/2005US20050215489 Methods of treating diabetes using pde 11a inhibitors
09/29/2005US20050215488 Novel lincomycin derivatives possessing antibacterial activity
09/29/2005US20050215487 Conjugates comprising an nsaid and a sugar and uses thereof
09/29/2005US20050215455 Surfactants in powdered form that can be used in tablets or gelatin capsules; preparation process and compositions containing them
09/29/2005US20050214888 Using animal models to isentify modulators of cAMP responsive element binding protein (CREB) activity; for treatment and prevention of brain and cell proliferative disorders; antisense agents; antitumor agents
09/29/2005US20050214837 Antibody specific for mutant presenilin 1 and method of use thereof
09/29/2005US20050214780 Using polymorphism in potassium channel interacting protein (KChIP1) as diagnostic indicator for pancreatic disorders
09/29/2005US20050214761 For introducing DNA into organisms which produce large amounts of oils and, in particular, oils with a high content of unsaturated fatty acids
09/29/2005US20050214434 Preparation method of the conjugated linoleic acid diglycerides
09/29/2005US20050214392 Treatments for immune systems disorders
09/29/2005US20050214390 Bioavailability enhancing activity of Carum carvi extracts and fractions thereof
09/29/2005US20050214389 Beta-carotene enriched extract from water hyacinth eichhornia crassipes
09/29/2005US20050214388 Multivitamin formulations containing controlled-release magnesium
09/29/2005US20050214385 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia
09/29/2005US20050214384 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
09/29/2005US20050214383 Multi-vitamin and mineral nutritional supplements
09/29/2005US20050214378 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
09/29/2005US20050214375 Process for producing block copolymer/drug composite
09/29/2005US20050214373 Coated tablet formulation and method
09/29/2005US20050214372 Stable pharmaceutical composition comprising an acid labile drug
09/29/2005US20050214371 Stable pharmaceutical composition comprising an acid labile drug
09/29/2005US20050214368 Controlled release formulations using intelligent polymers
09/29/2005US20050214366 Anti-first-pass effect compounds
09/29/2005US20050214364 Products and methods for treating vaginal infections
09/29/2005US20050214363 Administering an immediate release oral dosage of diclofenac or in salt form together with one or more alkali metal bicarbonates in an amount of >20% by weight; palatable and free from any unpleasant taste or side effects; short time to the maximum plasma concentration; high maximum plasma concentration
09/29/2005US20050214361 Shell contains non-water-soluble light-shielding agent, with medicine encapsulated within
09/29/2005US20050214360 Diclofenac sodium oral pharmaceutical
09/29/2005US20050214353 Matrix for administering ergoline compounds such as lisuride; restless leg syndrome; circadian rhythm disorders; Parkinson's disease
09/29/2005US20050214352 Patch and process for producing the same
09/29/2005US20050214346 For reducing serum cholesterol by increasing high density lipoprotein concentration; hypercholesterolemia
09/29/2005US20050214345 Artificial biocompatible material as a support for cells in a retinal implant
09/29/2005US20050214343 Such as 4,4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2pyrimidinyl]amino]-phenyl]benzamide methanesulfonate ((imatinib mesylate); stents; catheters
09/29/2005US20050214341 Three dimensional, malleable cell culture; tissue engineering; pluripotent cells
09/29/2005US20050214338 N-methylaspartic acid (NMDA) receptor antagonist such as ketamine
09/29/2005US20050214336 Via phenylketoenol derivatives
09/29/2005US20050214328 Administering an immunomodulatory compound (1-oxo- or 1,3-dioxo-2-(2,6-dioxopiperidin-3yl) isoindolines); inhibiting cell growth or proliferation, removing or improving acne scar, or reducing or correcting wrinkle line; senile keratosis
09/29/2005US20050214294 Diabetic nephropathy therapies
09/29/2005US20050214275 Noninvasive fat modulation; utilizing active agents having reactive selectivity to metabolic regulatory system of cells; drug screening; animal models
09/29/2005US20050214265 Tolerance conditioning and multiday delayed transplantation; depleting alpha beta - and gamma delta -TCR+ T cells and/or CD8+ T cells
09/29/2005US20050214262 Population of hematopoietic cells, made to exhibit a greater clonogenic potential, engraftment potential, immune system reconstitution potential and/or proportion of CD34+ positive cells by culturing with a transition metal compound that chelates copper such as tetraethylenepentamine
09/29/2005US20050214255 N-acylated chitinous polymers and methods of use thereof
09/29/2005US20050214250 Method of preparing carboxylic acid functionalized polymers
09/29/2005US20050214249 Release nitric oxide under physiological conditions and are useful for treating biological disorders
09/29/2005US20050214247 Glycodendrimers having biological activity
09/29/2005US20050214246 Poly(potassium and sodium styrene sulfonate), its manufacture and its uses
09/29/2005US20050214229 Two-stage transmucosal medicine delivery system for symptom relief
09/29/2005US20050214228 Uniform powder production; controlling relative stream velocity, solution concentration and proportion of solvent to antisolvent; preventing liquid inclusion
09/29/2005US20050214223 Abuse-safeguarded dosage form
09/29/2005US20050211192 Animal cover having a temperature altering device
09/29/2005DE10393402T5 Mittel und Toilettenartikel- oder pharmazeutische Zusammensetzung zum Beschleunigen der Aufnahme von basischen Aminosäuren in Zellen Means and Toilettenartikel- or pharmaceutical composition to accelerate the uptake of basic amino acids in cells
09/29/2005DE10361596A1 Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform A process for preparing a secured against abuse dosage form
09/29/2005DE102004013227A1 Production of 3-beta-aminonortropane derivatives, useful as e.g. N-methyl-D-aspartate receptor modulators, or synthetic intermediates, comprises preparing an imine, converting the imine into a stable tautomer or isomer, and hydrolyzing
09/29/2005DE102004012070A1 Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel New cycloalkyl-containing 5-Acylindolinone, their preparation and their use as medicaments
09/29/2005DE102004012069A1 Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel New aryl-containing 5-Acylindolinone, their preparation and their use as medicaments
09/29/2005DE102004012068A1 Neue alkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel New alkyl-containing 5-Acylindolinone, their preparation and their use as medicaments
09/29/2005DE102004012045A1 Solid pharmaceutical composition containing tropane type inhibitor of neurotransmitter reuptake, useful for treating central nervous system disorders
09/29/2005DE102004012009A1 Antidandruff compositions, e.g. shampoos, containing synergistic active agent combination of acetylsalicylic acid, zinc pyrithione and piroctone olamine
09/29/2005DE102004009325A1 Use of tropisetron having 5-hydroxytryptamine-3 receptor antagonistic activity for preventing the blocking of 5-hydroxytryptamine-3 receptor in organ transplant rejection reaction in transplanted organs e.g. heart, lungs, kidney or liver
09/29/2005CA2562388A1 Emulsion-stabilized preparation
09/29/2005CA2560767A1 Novel crystal of triterpene derivative
09/29/2005CA2560650A1 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation
09/29/2005CA2560298A1 Preparation with elevated content
09/29/2005CA2560286A1 Substituted quinazoline or pyridopyrimidine derivative
09/29/2005CA2560282A1 Crystalline form of atorvastatin hemi calcium
09/29/2005CA2560279A1 Use of a 5-ht3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain
09/29/2005CA2560269A1 Combinatorial methods and compositions for treatment of melanoma
09/29/2005CA2560267A1 Methods for increasing neurotransmitter levels using hydroxycitric acid
09/29/2005CA2560266A1 Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
09/29/2005CA2560253A1 Prodrugs of piperazine and substituted piperidine antiviral agents
09/29/2005CA2560226A1 Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
09/29/2005CA2560206A1 7, 8, 9, 10- tetrahydro-imidazo [2,1-a] isoquinoline derivatives and their use as gastric acid secretion inhibitors
09/29/2005CA2560199A1 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
09/29/2005CA2560195A1 Organic compounds
09/29/2005CA2560157A1 New quaternized quinuclidine esters
09/29/2005CA2560059A1 Platinum carboxylate anticancer compounds
09/29/2005CA2560035A1 Control of feeding behavior by changing neuronal energy balance
09/29/2005CA2560024A1 Intranasal benzodiazepine compositions
09/29/2005CA2559972A1 Benzamide and benzoate anti-hiv compounds
09/29/2005CA2559955A1 Methods and compositions for the specific inhibition of gene expression by double-stranded rna
09/29/2005CA2559919A1 Sulphonamide derivatives
09/29/2005CA2559743A1 Methods for treating alcoholism
09/29/2005CA2559742A1 Methods for treating alcoholism
1 ... 4524 4525 4526 4527 4528 4529 4530 4531 4532 4533 4534 4535 4536 4537 4538 4539 4540 4541 4542 4543 4544 ... 7860